• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pulmonary Fibrosis Foundation, Biogen Idec partner on PFF Patient Registry

Pulmonary Fibrosis Foundation, Biogen Idec partner on PFF Patient Registry

June 11, 2014
CenterWatch Staff

The Pulmonary Fibrosis Foundation (PFF) has partnered with Biogen Idec to support the PFF Patient Registry.

"Our partnership with Biogen Idec will further enhance the PFF Patient Registry, allowing us to investigate fundamentally important questions in pursuit of our mission to improve the lives of patients with pulmonary fibrosis and one day identify a cure," said Gregory P. Cosgrove, M.D., chief medical officer for the foundation. Cosgrove is associate professor of medicine in the Pulmonary, Critical Care and Sleep Medicine at National Jewish Health and the University of Colorado-Denver.

Shelia Violette, senior director research at Biogen Idec, said, "The more we learn about rare diseases like pulmonary fibrosis, the more we improve the chances of discovering and developing therapies that can make a truly meaningful difference in patients' lives."

Once established, the PFF Patient Registry will become the largest collection of pulmonary fibrosis (PF) patient data in the world. With additional resources, the registry will be able to collect more in-depth data as well as biologic and radiographic samples from those living with PF. This data will be made available to qualified investigators who are looking to gain a better understanding of the disease, make new observations about who gets PF and why, and develop more effective treatments.

"The dissemination of findings from the Registry though publications, educational programs, and the CCN extends the value of the registry well beyond the pilot sites, with a primary goal of improving the overall care of patients with PF everywhere," said Kevin R. Flaherty, M.D., MS, Steering Committee chairman for the PFF Care Center Network and the PFF Patient Registry.

Importantly, because these data will be collected in a standardized way at all sites, accurate and meaningful results will be obtained each time the data are analyzed. The value of the registry will be recognized as investigators at and beyond the pilot sites utilize the data and samples to learn more about the biological mechanisms of PF, develop effective clinical care patterns and treatments and facilitate enrollment in clinical trials.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing